About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: IMMY
- Previous Close: $2.54
- 50 Day Moving Average: $2.49
- 200 Day Moving Average: $3.01
- 52-Week Range: $1.65 - $4.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.94
- P/E Growth: -0.14
- Market Cap: $33.66M
- Outstanding Shares: 13,253,000
- Beta: 0.61
- Net Margins: -102.59%
- Return on Equity: -457.59%
- Return on Assets: -87.29%
Companies Related to Imprimis Pharmaceuticals:
- Debt-to-Equity Ratio: 3.94%
- Current Ratio: 1.55%
- Quick Ratio: 1.22%
What is Imprimis Pharmaceuticals' stock symbol?
Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."
Where is Imprimis Pharmaceuticals' stock going? Where will Imprimis Pharmaceuticals' stock price be in 2017?
2 brokers have issued 12-month target prices for Imprimis Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Imprimis Pharmaceuticals' stock price to reach $5.00 in the next year.
When will Imprimis Pharmaceuticals announce their earnings?
Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.
Who owns Imprimis Pharmaceuticals stock?
Imprimis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (5.43%) and Bard Associates Inc. (0.49%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Donald Paul Miloni, Mark L Baum, Opaleye Management Inc and Richard L Md Lindstrom.
Who sold Imprimis Pharmaceuticals stock? Who is selling Imprimis Pharmaceuticals stock?
Imprimis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and Bard Associates Inc..
How do I buy Imprimis Pharmaceuticals stock?
Shares of Imprimis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Imprimis Pharmaceuticals stock cost?
One share of Imprimis Pharmaceuticals stock can currently be purchased for approximately $2.60.